84 terminated. 84 Phase 2, 19 Phase 1, 11 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 84 | Terminated 84 |
| Phase 1 | 19 | Terminated 19 |
| Phase 3 | 11 | Terminated 11 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Batoclimab - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Immunovant Sciences GmbH | 26 | 2025-08-28 | 2026-08-11 |
| Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP NVG-2089 - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Nuvig Therapeutics, Inc. | 14 | 2025-04-25 | 2026-10-06 |
| A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis LY3541860, Placebo - Multiple Sclerosis | Phase 2 | Terminated | Eli Lilly and Company | 63 | 2024-03-19 | 2026-09-23 |
| A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis SAR443820, Placebo - Multiple Sclerosis | Phase 2 | Terminated | Sanofi | 174 | 2022-12-19 | 2025-10-15 |
| To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Immunovant Sciences GmbH | 94 | 2022-12-15 | 2026-08-11 |
| A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN) SBT101 Treatment - AMN, AMN Gene Mutation | Phase 1 / Phase 2 | Terminated | SwanBio Therapeutics, Inc. | 9 | 2022-11-17 | 2026-08-26 |
| PET Imaging of Cyclooxygenase in Multiple Sclerosis 11C-MC1, 11C-PS13, Ketoprofen - Multiple Sclerosis | Phase 2 | Terminated | National Institute of Mental Health (NIMH) | 7 | 2022-06-07 | 2024-06-27 |
| An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients zanubrutinib - Neuromyelitis Optica | Phase 2 | Terminated | Xuanwu Hospital, Beijing | 6 | 2022-05-07 | 2026-04-27 |
| Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis Mayzent, Ocrevus - Secondary-progressive Multiple Sclerosis | Phase 2 / Phase 3 | Terminated | State University of New York at Buffalo | 8 | 2021-11-13 | 2025-05-13 |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 32 | 2021-11-02 | 2026-05-27 |
| Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis Belimumab, Short-course Ocrelizumab, Continued Ocrelizumab - Multiple Sclerosis | Phase 2 | Terminated | Johns Hopkins University | 4 | 2021-10-01 | 2023-03-07 |
| A Long-term Extension of Study GNC-401 Temelimab 18 mg/kg, Temelimab 36mg/kg, Temelimab 54 mg/kg - Multiple Sclerosis | Phase 2 | Terminated | GeNeuro Innovation SAS | 33 | 2021-08-27 | 2022-07-07 |
| Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial Autologous Hematopoietic Stem Cell Transplantation, Ocrelizumab, Alemtuzumab - Relapsing-Remitting Multiple Sclerosis | Phase 2 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 1 | 2021-08-27 | 2022-03-16 |
| COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders Moderna mRNA-1273, BNT162b2, Ad26.COV2.S - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 258 | 2021-08-13 | 2026-06-10 |
| RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial RC18 160mg, RC18 240mg - Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Terminated | RemeGen Co., Ltd. | 8 | 2021-05-13 | 2026-04-13 |
| A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 68 | 2020-09-28 | 2026-03-31 |
| Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis? Evaluation of degree chronic fatigue., Questionnaires, Blood sample - Sclerosis, Multiple | Phase 2 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 67 | 2020-01-21 | 2023-11-02 |
| A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder Eculizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 5 | 2020-01-14 | 2024-09-25 |
| Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis Melatonin, Placebo - Sclerosis, Multiple, Autoimmune Diseases of the Nervous System | Phase 1 / Phase 2 | Terminated | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 25 | 2019-11-29 | 2026-02-20 |
| Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis CNM-Au8, Placebo - Relapsing Remitting Multiple Sclerosis, Optic Neuropathy | Phase 2 | Terminated | Clene Nanomedicine | 73 | 2018-11-23 | 2023-04-03 |
Showing 20 of 84. Sign in to see all of them.
Multiple Sclerosis (50) · Multiple Sclerosis, Relapsing-Remitting (22) · Autoimmune Diseases (7) · Multiple Sclerosis, Chronic Progressive (6) · Muscle Spasticity (5) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (4) · Adrenoleukodystrophy (3) · Fatigue (3) · Leukodystrophy, Metachromatic (3) · Metabolism, Inborn Errors (3) · Neuromyelitis Optica (3) · Recurrence (3) · Leukodystrophy, Globoid Cell (2) · Marijuana Abuse (2)
Nervous System Diseases (82) · Autoimmune Diseases of the Nervous System (77) · Immune System Diseases (77) · Demyelinating Autoimmune Diseases, CNS (74) · Autoimmune Diseases (71) · Pathological Conditions, Signs and Symptoms (29) · Multiple Sclerosis (20) · Pathologic Processes (18) · Disease Attributes (14) · Signs and Symptoms (13) · Chronic Disease (10) · Neurologic Manifestations (10) · Central Nervous System Diseases (9) · Neuromuscular Diseases (9)
Alemtuzumab (4) · Adrenocorticotropic Hormone (2) · Cyclophosphamide (2) · Methylprednisolone (2) · Minocycline (2) · Saline Solution (2) · Stem Cell Transplantation (2) · ocrelizumab (2) · temelimab (2) · (11C)-MC1 (1) · 11C-PS13 (1) · 2-(6-chloro-2-(4-(3-fluoropropoxy)phenyl)imidazo(1,2-a)pyridin-3-yl)-N,N-diethylacetamide (1) · 2019-nCoV Vaccine mRNA-1273 (1) · Abatacept (1) · Acetazolamide (1)
Charite University, Berlin, Germany (4) · Biogen (2) · EMD Serono (2) · Eli Lilly and Company (2) · Genzyme, a Sanofi Company (2) · Immunovant Sciences GmbH (2) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2) · Merck KGaA, Darmstadt, Germany (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Novartis Pharmaceuticals (2) · US Department of Veterans Affairs (2) · University of Calgary (2) · Academic MS Center Limburg (1) · Albert Saiz (1) · Alexion Pharmaceuticals, Inc. (1)
United States (40) · Germany (19) · Spain (18) · Canada (17) · Poland (16) · Italy (15) · United Kingdom (11) · France (10) · Russia (10) · Belgium (9) · Czechia (9) · Sweden (7) · Hungary (6) · Serbia (6) · Ukraine (6)
Albert Lo, MD PhD (2) · Arnon Karni, MD (2) · Adam F Carpenter, MD (1) · Alasdair Coles, Phd FRCP (1) · Albert Saiz, MD (1) · Amit Bar-Or, MD, FRCP (1) · Antonio Carrillo Vico, PhD (1) · Berit Rosche, M.D. (1) · Bibiana Bielekova, M.D. (1) · Blayne Welk, MD MSc (1)
PMID 12542793, PMID 15864738, PMID 19092106, PMID 21586746, PMID 22316314, PMID 23733308, PMID 23782752, PMID 23982748, PMID 24759263, PMID 25436769, PMID 25442786, PMID 26298797, PMID 26590659, PMID 27574516, PMID 29755397, PMID 31063156, PMID 31072380, PMID 31075187, PMID 31928294, PMID 32047645, PMID 32126977, PMID 32830462, PMID 33332761, PMID 34240656, PMID 36126241, PMID 36418156, PMID 37036134, PMID 37345645, PMID 37626477, PMID 38010108, PMID 38104476, PMID 38241758, PMID 38335474, PMID 38353301, PMID 41289027, PMID 41454463, PMID 41706381
2014 (3), 2005 (2), 2008 (2), 2023 (2), 2016 (1), 2017 (1), 2018 (1), 2019 (1), K23AT004433 (1)